Objective: To compare results of treatment of adenocardinoma of the prostate using Standard (2D) vs Conformal (3D) treatment planning.
Introduction
Conformal radiotherapy using three dimensional beamseye-view planning (3D) may allow more accurate and precise delivery of radiation minimizing the amount of normal tissue in the high dose region. Single institutional non-randomized studies comparing conventional twodimensional (2D) vs 3D-planning have suggested an improvement in biochemical control without an increase in complications. 1±3 These comparisons have usually been part of a dose escalation study.
1,4 ± 6 Therefore, it is not clear whether the bene®t of 3D-planning is from a higher dose or more accurate delivery. Until recently, there had not been a published randomized study comparing 2D-planning against 3D-planning except for the study by Pollack et al 7 which only used the 3D-planning for the boost. Yang et al 8 recently reported on the acute toxicity during a course of irradiation to the prostate in a small randomized trial of 3D vs 2D treatment planning. The purpose of the present study is to compare and present the preliminary results in contemporary populations of patients treated to similar doses with radiotherapy alone for adenocarcinoma of the prostate with either 2D-or 3D-planning used to determine the volume irradiated for the entire treatment course.
Methods
The records of all patients with adenocarcinoma of prostate treated with curative intent with radiation therapy only between July 1, 1991, and June 30, 1994, were reviewed. Inclusion criteria were: biopsy proven adenocarcinoma of the prostate; no radiographic evidence of distant metastases; clinically localized disease (T 1± 4 , N 0 ±1 , M 0 ); intact prostate treated with radiotherapy alone with curative intent; no concurrent hyperthermia; no neoadjuvant or concurrent hormonal therapy; all radiation therapy planning done using either standard 2D-or 3D-planning; and no history of other malignancy in the previous ®ve years except for localised skin cancers.
All patients underwent a complete pre-treatment history and physical. Laboratory evaluation was generally limited to a complete blood count, prostate speci®c antigen (PSA) and creatinine. Radiographic evaluation usually included a diagnostic or treatment planning computed tomography (CT) scan of the pelvis and bone scan. Pelvic lymph nodes were evaluated by CT scan and infrequently by lymphangiography or node dissection. The 1992 AJCC TNM staging system for prostate cancer was used to assign clinical T-stage. 9 The decision to treat patients using 2D-or 3D-planning techniques was based solely upon the availability of the technology. During the study period, 3D-planning was only available at Duke University. All 3D patients were planned at Duke University, and all but one were treated at Duke University. 2D-planned patients were treated primarily at the af®liated hospitals.
2D patients were simulated in the supine position. Anterioposterior (AP) and either right or left lateral localization ®lms were taken on the simulator. Contrast was instilled into the bladder and rectum through a foley catheter and rectal tube to better delinate these structures on the lateral ®elds. The prostate and seminal vesicles were manually transposed onto the simulator ®lms by the physican generally using a diagnostic or treatment planning CT. After identi®cation of the location of the prostate, seminal vesicles, bladder, and rectum, custom blocks were drawn to protect the normal tissues. A four-®eld box technique was used (AP, PA, right and left laterals). Initial ®elds included the prostate, seminal vesicles, and periprostatic tissues. The pelvic lymph nodes were not routinely treated. Coverage of the seminal vesicles in the boost ®eld was at the discretion of the attending radiation oncologist. The initial ®elds covered the prostate and seminal vesicles with a ! 2 cm margin. Customized isodose maps were generated for each patient and doses were prescribed to the ®rst isodose line that completely covered the target volume (usually 95±98% isodose line).
3D patients were immobilized in a customized foam cradle in the supine position as previously reported by Bentel et al. 10 A CT scan was taken (5 mm scan interval) from below the inferior pubic rami to the top of the iliac crests with the patient in the treatment position in the cast. In patients with adequate renal function, 150 cc of contrast was injected intravenously immediately prior to scanning to better delinate the prostatic apex as well as the interfaces between the prostate and bladder or rectum. Anatomic structures were outlined on each CT slice and ®elds were designed using beams-eye-view. In general, the four-®eld box technique was used. The initial ®elds covered the prostate and seminal vesicles with a 2 cm margin. Individualized isodose maps were generated and doses were prescribed to the ®rst isodose line that completely covered the target volume (usually 95± 98%).
For all patients, all ®elds were treated each day, ®ve days per week at 1.8±2.0 Gy per day to a total dose of 44 ± 46 Gy. The ®elds were then reduced to cover the prostate to a total dose of 64±70 Gy. All patients were treated on linear accelerators using 6 ±15 MV photons.
Patients were usually seen 4 ±6 weeks after completing radiotherapy and then at 3±6 month intervals. Besides the history and physical, a PSA was obtained at each followup visit. Other laboratory or radiographic studies were obtained only if dictated by symptoms.
The end-points of the study were: survival, local control, distant failure, biochemical control, disease free survival (DFS), and complications. Local control was determined by digital rectal exam, usually without biopsy con®rmation. Distant failure was determined clinically andaor radiographically. Biochemical failure was de®ned as a rising PSA of at least 10% on two measurements ! 1 month apart. Data were analysed using either a nadir PSA (nPSA) b4 ngaml or b1 nga,ml. DFS was de®ned as no evidence of local, distant, or biochemical failure.
Complications were divided into acute (`6 months after the completion of radiotherapy) or late (b6 months after radiotherapy). Complications were scored according to RTOG criteria. 11 Survival curves were estimated by the Kaplan±Meier method. 12 The Cox±Mantel test was used to compare survival and outcome distributions, and the P-values reported refer to differences between survival distributions between two groups as calculated from the Cox± Mantel test. 13 The Chi-square statistic was used for comparisons in tables. The Wilcoxon rank sum test was used for distributions such as pre-treatment PSA.
Results
The characteristics of the two patient groups are shown in Table 1 . Fewer 2D patients had a diagnostic CT while fewer 3D patients had bone scans. The median follow-up after the completion of radiotherapy was signi®cantly shorter for 3D group. Although these differences were statistically signi®cant, they were not clinically signi®-cant. There was no signi®cant difference in the T-stage distribution, pre-treatment PSA, dose range or median dose between the groups. The tumor grade was similar between the groups (see Table 2 ).
The two-year actuarial over-all survival rates were 95% for 2D and 98% for 3D P 0X261. The two-year actuarial DFS rates using a nPSA`4.0 ngaml were 70% for the 2D and 68% for the 3D P 0X312; the rates using a nPSA 1.0 ngaml were 51% and 53% P 0X991, respectively, see Figure 1 . The two-year actual local control was 93% for the 2D and 96% for 3D P 0X345. The two-year actuarial PSA control (nadir 4.0 ngaml) was 72% for 2D and 71% for 3D P 0X861; the rates using a nPSA 1.0 ngaml were 51 and 53% P 0X881, respectively, see Figure 2 ). The two-year actuarial PSA control (nadir 4.0 ngaml) for patients (both groups) with a pre-treatment PSA 10.0 ngaml was 87 vs 61% for a pre-treatment PSA b 10.0 ngaml P`0X001; the rates using nPSA 1.0 ngaml were 70 and 37% P`0X001, respectively, see Figure 3 .
The analysis of bladder and rectal complications revealed a higher rate of acute complications for 3D but no difference in late complications, see Table 3 .
Discussion
Conformal radiation treatment planning using beamseye-view approaches has been supported by the principle that better targeting to the tumor permits more accurate dose delivery with a reduction of the volume of normal tissue treated to high dose. 3 Studies such as that by Soffen et al 2 have shown a decreased need for medication or treatment interruption for acute toxicities in conformally treated patients, and Hanks et al 1 have shown a decreased rate of acute grade 2 morbidity with conformal treatment. However Yang et al 8 showed no difference in the acute toxicity during treatment in a small randomized study. Our study is the ®rst to analyse disease control and complications retrospectively for a contemporary cohort of patients treated to the same dose again using 2D-or 3D-planning. The decision to use 2D-or 3D-planning was based on the availability of the technology at a given location rather than other factors that might introduce selection bias. Our ®ndings suggest, in terms of either disease control and complications, that careful 2D-planning yields satisfactory results comparable to 3D-planning in the dose range of 64±70 Gy. Furthermore, the frequencies of severe complications with either carefully planned and administered 2D or 3D radiotherapy for prostate cancer are quite low.
Sandler et al 5 found a low risk of chronic rectal morbidity in patients treated conformally for prostate cancer. With a median follow-up of 20.4 months, the three year actuarial risk of Grade 3 rectal complication was 3%. The dose range was 59.4±80.4 Gy (median 68.4 Gy). The median follow-up was similar to our 3D group and shorter than our 2D group. The median dose was similar to that in our study but with a greater dose range. In our study, the two year actuarial rates of Grade 3a4 rectal complications (2D ±1% and 3D ± 0%, Table 3 ) were similar to those found by Sandler et al. Schultheiss et al 6 reported on the incidence of late complications (grades 3a4) for conformal and conventional radiation treatment of prostate cancer for 616 patients treated to b65 Gy with b3 month follow-up.
Prostatectomy patients were excluded. Conventional radiation therapy was not de®ned. The median doses were reported by year and treatment method and ranged from 68 ±72 Gy. The median follow-up periods were divided by dose group and ranged from 16 ±52 months. Their study showed a ®ve year actuarial incidence of genitourinary (GU) and gastrointestinal (GI) complications of 3.4% and 2.7%, respectively. No factors were noted to be predictive for GU morbidity, but dose and age were predictive for GI morbidity. The authors stated that the use of conformal ®elds did not reduce the Standard vs conformal radiation therapy JM Bean et al incidence of late GI morbidity, although these patients were treated to higher doses on average than conventionally treated patients which may account for this ®nding. The complication rates reported by Schultheiss et al 6 are slightly higher than the present series (Table 3) ; however, their median doses were also slightly higher, which may be responsible for this difference.
Few studies are available which compare the biochemical control rates with conventional vs conformal radiotherapy. Corn et al 4 reported on the PSA response at one year in patients treated conformally or conventionally as a measure of disease control. The conventional treatment used is different from the present study in that rectangular ®elds AE corner block were used. The median tumor doses were slightly higher at 70 Gy conventional and 70.2 Gy conformal compared to 67 Gy and 66.6 Gy respectively in the present study. They reported a PSA normalization (PSA 4 ngaml) by one year of 96% in the conformal and 85% in the conventional group. In our study, 87.6% of the 3D and 88.9% of the 2D group had the nPSA 4 ngaml. Corn et al 4 suggested that`an inherent bene®t of conformal techniques is the more accurate and precise deposition of prescribed irradiation dose within the target.' However, we contend that with more accurate standard techniques that no bene®t is seen within this dose range.
Pollack et al 7 reported a phase II randomized study of conventional vs conformal radiation techniques for prostate cancer which randomized between 78 Gya39 fractions (conformal) and 70 Gya35 fractions (conventional). All patients received 46 Gy with a four-®eld non-conformal technique followed by boost which used four non-conformal ®elds in the conventional group or six conformal ®elds in the conformal group. They reported on the ®rst 60 patients in the protocol (29 conformal and 31 conventional). Median follow-up was not stated. There was no difference in acute toxicity or early biochemical response although the conventional group had slightly better early PSA responses. Therefore, this study found no advantage in terms of disease control for the use of a conformal boost. However, the conformal boost technique did permit escalation of the radiation dose by 10% without an increase in complications.
In our preliminary review of two contemporary groups of patients treated with radiation therapy alone who differed only in the method of treatment planning and delivery, we found no improvement in any outcome measure with 3D-planning. Therefore at this time, we believe it is reasonable to use either careful 2D or 3D-planning as described if the planned dose is 70 Gy.
There are circumstances where it may be necessary to increase the dose to the prostate tumor beyond 70 Gy in order to obtain a satisfactory outcome. In a report by Kavadi et al, 4 it was found that only those patients who have a nPSA`1 ngaml have a favorable DFS. They also showed that as the pre-treatment PSA increased, the likelihood of achieving a nPSA`1 ngaml decreased. In their study, 150 out of 231 (65%) patients whose pre-treatment PSA was 10 ngaml achieved a nPSA`1 ngaml. In contrast, only 32 out of 189 (16.9%) patients with a pre-treatment PSA b 10 ngaml achieved a nPSA`1 ngaml P`0X001. The dose given ranged from 60±68 Gy with increasing doses given for increasing Tstage. Our data also shows that those patients with a pretreatment PSA b 10 ngaml have a signi®cantly worse biochemical outcome regardless of nPSA used. Furthermore, Zagars et al 15 have suggested that most of the pre-treatment PSA in patients with clinically localized disease comes from the tumor in the prostate. These data would suggest that patients with pre-treatment PSA b 10 ngaml may require doses above 70 Gy.
Hanks et al 16, 17 indicate that patients with pre-treatment PSA ! 10 ngaml had improved biochemical outcomes with doses above 71 or 73 Gy. They reviewed 375 conformally treated patients with dose escalation from 66±79 Gy. The median follow-up was 21 months from the onset of radiation treatment. Biochemical failure was de®ned as PSA ! 1.5 ngaml and rising on two consecutive values. For patients with a pre-treatment PSA`10 ngaml, the two year biochemical control rates were 93±94% whether analysed above or below 71 or 73 Gy. For those patients with a pre-treatment PSA ! 10 ngaml, the two year biochemical control rates were 48% for`71 Gy vs 79% for ! 71 Gy P 0X0001 and for`73 Gy, the rate was 60% compared to 81% for ! 73 Gy P 0X004. For patients at high risk for recurrence, the potential bene®t of dose escalation above 73 Gy is a 50% reduction in the two year failure rate.
Hormonal manipulation has also been used as a means to improve tumor control for patients at high risk of failure. Pollack et al 18 showed an 81% reduction in the three year rate of rising PSA for patients treated with radiation and androgen deprivation as compared to those treated with radiation alone. In the EORTC randomized trial of radiation AE androgen ablation, there were signi®-cant improvements in local control, metastatis free survival, clinical disease free survival, and overall survival with the addition of androgen ablation. In this trial, there was an 80% reduction of local failure, 75% reduction in metastasis, 73% reductioin in clinical failure, and a 50% reduction in mortality. 19 Thus, these data indicate that hormonal manipulation may have a greater role in treatment than will dose escalation.
In order to further explore the relative merits of higher doses of radiotherapy using 3D technology vs standard 2D therapy with androgen deprivation, we performed a cost comparison based upon several different published treatment regimes 16, 18, 19 including the current study. We normalized cost relative to a 70 Gy treatment course using 2D planning. The relative costs of the regimes were as follows: 70 Gy using 3D conformal radiotherapy (3DCRT): 1.1; 88 Gy using 3DCRT: 1.28; 70 Gy (2D) plus four months of LHRH agonist as per Pollack et al 18 : 1.12; and 70 Gy (2D) plus three years of LHRH agonist and one month of Casodex per Bolla et al 19 : 1.95. Thus, costs vary widely depending upon the regimen used. Whether very high dose 3DCRT is more effective and less costly than standard radiotherapy plus androgen deprivation can only be determined by a prospective randomized trial.
